# About Thymulin Direct: An Independent Research Digest

> Thymulin Direct is an independent editorial project that publishes plain, cited summaries of the peer-reviewed thymulin research literature. Not a clinic, not a vendor.

An independent research digest that puts the figure first and the caveat right beside it.

## What This Site Is

Thymulin Direct is an independent editorial project that publishes summaries of the peer-reviewed research literature on thymulin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The approach is data-forward by design: lead with what was measured, attribute it to the study that measured it, and state the limits in the same breath. Thymulin is a thin-literature compound with a few sharply-quantified facts — 858.86 Da, nine residues, active only 1:1 with zinc, a 1/100/1000 ng anti-hyperalgesia ladder — and a hard set of gaps, including no established human dose and an uncharacterized human half-life. We report both, side by side, without hype and without hedging the findings into invisibility.

## What 'Direct' Means Here

The word 'direct' in the name is editorial framing, not a service claim. It means plain, unhedged, numbers-first delivery — a research digest that prints the figure first and the source beside it, then the caveat. It does not mean we sell thymulin, source it, ship it, or connect anyone to a supplier. There is no store here and no checkout.

That distinction matters because the subject is widely misrepresented online. Consumer pages routinely conflate thymulin with thymosin alpha-1 and with thymalin (a bovine thymic complex); they are chemically and pharmacologically distinct compounds [16]. Some pages also quote specific consumer numbers from small, single-author pilot studies as if they were settled science; we treat those as preliminary and say so. Our job is to keep the record straight.

## How We Handle the Evidence

Every quantitative claim on this site maps to a numbered citation in the [thymulin references](/references). We distinguish what the published literature genuinely establishes — the zinc-coinage experiment [1], the human zinc-status link [3], the rodent dose ladder [8] — from what remains a research proposal, such as the PAT-analog direction for neuroinflammation [11].

Where the data stop, we leave the line blank rather than fill it. There is no established human thymulin dosage [2], no validated human pharmacokinetic half-life [2], and no large modern human efficacy trial of the native peptide [16]. Reading the evidence and its limits together is the whole point of the digest.

---

A numbers-first reading of the thymulin record — every figure pinned to its study, the 1:1 zinc-bound active form kept distinct from the inactive apopeptide and from thymosin alpha-1, and the empty human-dose and human-PK lines left openly unfilled; no clinic behind the poster and nothing here dosed, dispensed, or sold.